



**UNITED STATES
NUCLEAR REGULATORY COMMISSION**
REGION I
2100 RENAISSANCE BLVD.
KING OF PRUSSIA, PA 19406-2713

February 4, 2021

Carine Boustany, Ph.D., Global Head
Development Science + Head, Development Site US
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road,
Ridgefield, CT 06877

SUBJECT: BOEHRINGER INGELHEIM PHARMACEUTICALS INC., ACCEPTANCE OF
NOTIFICATION OF CHANGE OF MANAGEMENT REPRESENTATIVE, MAIL
CONTROL NO. 624169

Dear Dr. Boustany:

This is in reference to your letter dated December 18, 2020, notifying the NRC that you will be the management representative for the license. We have updated our records. No further correspondence on this matter is required.

Your cooperation is appreciated.

Sincerely,

Steve Shaffer, Senior Health Physicist
Commercial, Industrial, R&D
and Academic Branch
Division of Nuclear Materials Safety
Region I

Docket No. 030-17101
License No. 06-19183-01
Mail Control No. 624169

Enclosure: None

cc: Drane O'Brien, RSO

BOEHRINGER INGELHEIM PHARMACEUTICALS INC., ACCEPTANCE OF NOTIFICATION
OF CHANGE OF MANAGEMENT REPRESENTATIVE, MAIL CONTROL NO. 624169 DATED
FEBRUARY 4, 2021

DOCUMENT NAME: G:\WBL Documents\WBL License Cover Letter\L06-19183-01.624169.docx

SUNSI Review Complete: Steve Shaffer

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/end "E" = Copy w/ attach/end "N" = No copy

OFFICE	RI:DNMS						
NAME	SShaffer						
DATE	February 4, 2021						

OFFICIAL RECORD COPY